EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study

Henry O Herrera, Jeremy S Bordeaux

Journal of the American Academy of Dermatology · 2026-06 · 94 (6) · 1826-1827

DOI: 10.1016/j.jaad.2026.02.042 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of the American Academy of Dermatology, 2026-06. Verfasst von Henry O Herrera und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Case Western Reserve University, Cleveland, Ohio. Electronic address: hoh2@case.edu. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The widespread use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for type 2 diabetes and obesity has prompted investigation into their dermatologic side effects, including hair loss.1 Prior studies have associated semaglutide and tirzepatide with potential hair loss.2-4 This retrospective population-based cohort study used TriNetX, a multicenter database of de-identified electronic medical records, to evaluate whether patients treated with semaglutide and tirzepatide developed new-onset hair loss.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 receptor agonistalopeciaandrogenetic alopeciaelectronic health recordshair losssemaglutidetelogen effluviumtirzepatide

Autor:innen und Institutionen

  • Department of Dermatology, Case Western Reserve University, Cleveland, Ohio. Electronic address: hoh2@case.edu.
  • Department of Dermatology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio.

Zitieren

APA

Herrera, H. O., & Bordeaux, J. S. (2026). Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study. Journal of the American Academy of Dermatology, 94(6), 1826-1827. https://doi.org/10.1016/j.jaad.2026.02.042

Vancouver

Herrera HO, Bordeaux JS. Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study. Journal of the American Academy of Dermatology. 2026;94(6):1826-1827. doi:10.1016/j.jaad.2026.02.042

BibTeX
@article{Herrera2026,
  author = {Herrera, Henry O and Bordeaux, Jeremy S},
  title = {Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study},
  journal = {Journal of the American Academy of Dermatology},
  year = {2026},
  volume = {94},
  number = {6},
  pages = {1826--1827},
  doi = {10.1016/j.jaad.2026.02.042}
}
Kostenlos starten →